Compare Gilead Sciences, Inc. (GILD) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Petróleo Brasileiro SA — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Petróleo Brasileiro SA trades at $18.12 (market cap $114.31B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| GILD | PBR | |
|---|---|---|
Market Cap | $164.99B | $114.31B |
Sector | Health | Technology |
52-Week High | $155.80 | $22.03 |
52-Week Low | $110.56 | $11.54 |
Enterprise Value | $188.06B | $174.73B |
Dividend Yield | 2.47% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PBR trades at $17.96, down 3.02% today, with bearish technical signals but strong fundamentals. The company reported robust Q2 2026 results with record production of 3.34 million boe/day and net earnings surging 120% year-over-year. Valuation metrics remain attractive with P/E of 4.63 and ROE of 30.77%. Analyst consensus is bullish with 11 buy ratings out of 22 total coverage.
PBR presents a compelling value opportunity with strong profitability and dividend yield, though regulatory uncertainty and oil price volatility pose risks. The company's production growth trajectory and cost-efficient pre-salt assets support long-term upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
